Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Eton Pharmaceuticals (ETON) Other Non-Current Assets (2019 - 2025)

Eton Pharmaceuticals' Other Non-Current Assets history spans 7 years, with the latest figure at $19000.0 for Q3 2025.

  • For Q3 2025, Other Non-Current Assets rose 58.33% year-over-year to $19000.0; the TTM value through Sep 2025 reached $19000.0, up 58.33%, while the annual FY2024 figure was $12000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q3 2025 was $19000.0 at Eton Pharmaceuticals, up from $12000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $36000.0 in Q1 2021 and bottomed at $12000.0 in Q1 2022.
  • The 5-year median for Other Non-Current Assets is $12000.0 (2022), against an average of $15736.8.
  • The largest annual shift saw Other Non-Current Assets tumbled 71.6% in 2021 before it skyrocketed 58.33% in 2025.
  • A 5-year view of Other Non-Current Assets shows it stood at $21000.0 in 2021, then crashed by 42.86% to $12000.0 in 2022, then changed by 0.0% to $12000.0 in 2023, then changed by 0.0% to $12000.0 in 2024, then surged by 58.33% to $19000.0 in 2025.
  • Per Business Quant, the three most recent readings for ETON's Other Non-Current Assets are $19000.0 (Q3 2025), $12000.0 (Q2 2025), and $12000.0 (Q1 2025).